















400Clinical outcome after infrapopliteal bypass surgery
in chronic hemodialysis patients with critical limb
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Objective: Lower extremity bypass surgery has been widely performed to treat critical limb ischemia (CLI) in patients on
hemodialysis (HD). However, the clinical outcome still remains unclear. We investigated the limb salvage rate after
infrapopliteal bypass surgery in HD patients with CLI.
Methods: From April 2006 to January 2013, 226 patients with 236 limbs who electively underwent bypass surgery for
treatment of CLI due to infrapopliteal disease were enrolled. Patients were grouped by those who were on HD (n[ 177)
and those who were not (n [ 49). They were monitored for 5 years or until December 2013 if the follow-up period
was <5 years. Amputation-free survival, deﬁned as freedom from major amputation or all-cause death, was primarily
evaluated. Incidence of reintervention was also analyzed.
Results:Ulcer/gangrene was present in 206 patients (91.2%), and 233 limbs (98.7%) were treated using autogenous vein.
Age was younger (67 6 9 vs 72 6 9 years; P [ .0011) and ulcer/gangrene was more prevalent (93.8% vs 81.6%, P [
.0080) in HD patients than in non-HD patients. During the follow-up period (median, 28 months), 33 (14.6%) major
amputations and 28 reinterventions (12.4%) occurred, and 65 patients (28.8%) died. The 5-year amputation-free survival
rate was signiﬁcantly lower in HD patients than in non-HD patients (43.6% vs 78.8%, P [ .0033), and the adjusted
hazard ratio (HR) for amputation or death for HD patients was 2.36 (95% conﬁdence interval [CI], 1.13-4.92;
P [ .022). Compared with non-HD patients, the status of HD was similarly an independent risk of major amputation
(72.4% vs 92.5%; adjusted HR, 4.36; 95% CI, 1.04-18.3; P[ .045) and mortality (56.9% vs 83.2%; adjusted HR, 2.81;
95% CI, 1.30-6.09; P[ .0085). However, freedom from reintervention was comparable between the two groups (84.3%
vs 86.8%; P [ .89). In HD patients, body mass index (HR, 0.86; 95% CI, 0.76-0.96; per 1 kg/m2 increase; P [ .014)
and C-reactive protein (HR, 1.06; 95% CI, 1.01-1.11; P [ .014) independently predicted major amputation. Elevated
C-reactive protein levels were also associated with death (HR, 1.04; 95% CI, 1.01-1.09; P [ .047).
Conclusions: The clinical outcome after infrapopliteal bypass surgery was poorer in HD patients with CLI compared with
non-HD patients. Malnutrition or chronic inﬂammation was associated with poor outcome in HD patients with CLI due
to infrapopliteal occlusive disease. (J Vasc Surg 2015;61:400-4.)Even after lower extremity revascularization with surgi-
cal or endovascular procedures to treat critical limb
ischemia (CLI), the poorer prognosis, such as the high
incidence of major amputation or death, is consistently a
major clinical problem in patients on hemodialysis (HD)
compared with non-HD patients.1-3 Infrapopliteal artery
disease accounts for 25% of CLI patients,4 and one-third
to one-half of such patients have chronic renal insufﬁ-
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plasty is currently performed in chronic HD patients with
CLI, the utility also remains controversial.7-9 Bypass sur-
gery with autogenous vein has been widely performed in
many cases to treat CLI. We investigated the limb salvage
rate after infrapopliteal bypass surgery in chronic HD pa-
tients with CLI and evaluated the factors that might inﬂu-
ence the poor results associated with revascularization after
bypass surgery in HD patients.
METHODS
The study protocol was approved by the each hospital’s
Institutional Ethics Committee and conducted in accor-
dance with the Declaration of Helsinki. Physicians ob-
tained written informed consent from each patient.
Patients. This study was conducted as a retrospective
record review. From April 2006 to January 2013, the study
enrolled 226 CLI patients with 236 limbs electively under-
going bypass surgery for infrapopliteal artery lesions at
Nagoya Kyoritsu Hospital (Nagoya, Japan) and Matsunami
General Hospital (Kasamatsu, Japan). Patients who under-
went emergency surgery for acute limb ischemia were
excluded.
Table I. Clinical characteristics
Characteristicsa All patients (n ¼ 226) HD (n ¼ 177) Non-HD (n ¼ 49) P value
Male sex 162 (72) 132 (75) 30 (61) .055
Age, years 68 6 9 67 6 9 72 6 9 .0011
Diabetes 127 (56) 103 (58) 24 (49) .25
Hypertension 102 (45) 96 (54) 28 (57) .72
Dyslipidemia 39 (17) 31 (18) 8 (16) .84
Smoking 41 (18) 33 (19) 7 (14) .68
BMI, kg/m2 21.3 6 3.5 21.3 6 3.4 21.5 6 4.1 .72
Coronary artery disease 90 (40) 72 (41) 18 (37) .62
History of stroke 20 (9) 18 (10) 2 (4) .18
Indications .0080
Rest pain 20 (9) 11 (6) 9 (18)
Ulcer/gangrene 206 (91) 166 (94) 40 (82)
Preoperative ABI 0.63 6 0.35 0.65 6 0.37 0.59 6 0.29 .26
CRP, mg/L 19.5 (6.5-63.0) 21.5 (6.0-63.2) 14.0 (4.7-51.0) .24
Limbs, No. 236 184 52
Proximal artery .73
Common femoral 12 (5) 9 (5) 3 (6)
Distal SFA/above-knee popliteal 32 (14) 27 (15) 5 (10)
Below-knee popliteal/tibioperoneal trunk 192 (81) 148 (80) 44 (85)
Distal target artery .17
Tibioperoneal trunk 15 (6) 11 (6) 4 (8)
Anterior tibial 91 (39) 71 (39) 20 (38)
Posterior tibial 73 (31) 57 (31) 16 (31)
Fibular 9 (4) 4 (2) 5 (10)
Dorsal pedis 31 (13) 27 (15) 4 (8)
Plantar 17 (7) 14 (8) 3 (6)
Additional angioplasty in femoropopliteal artery 39 (17) 26 (14) 13 (25) .082
Bypass graft .62
Vein graft 233 (99) 182 (99) 51 (98)
Prosthetic graft 3 (1) 2 (1) 1 (2)
ABI, Ankle-brachial index; BMI, body mass index; CRP, C-reactive protein; SFA, superﬁcial femoral artery.
aCategoric data are presented as number (%) and continuous data as mean 6 standard deviation or median (interquartile range).
Fig 1. Kaplan-Meier estimated amputation-free survival (AFS) in
hemodialysis (HD) and non-HD patients. SE, Standard error.
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raphy to plan the appropriate approach and underwent
revascularization using regional anesthesia (epidural or spi-
nal). The primary choice of grafts was the ipsilateral or
contralateral single-segment great saphenous vein. Demo-
graphics, risk factors, including gender, age, diabetes, hy-
pertension, dyslipidemia, smoking status, body mass
index (BMI), serum C-reactive protein (CRP), and history
of cardiovascular disease, and indication of surgery, and
procedural variables were obtained from medical records
in each hospital.
Follow-up study. Patients were divided into two
groupsd177 on HD and 49 non-HD patients as a control
groupdand were routinely followed up at discharge, at 1, 3,
and 6 months for 1 year, and then at yearly intervals using
duplex ultrasound scans. Amputation-free survival (AFS), as
a composite end point deﬁned as freedom from amputation
above the ankle or any-cause death, was primarily evaluated.
The incidence of reintervention was also analyzed. These end
points were deﬁned as reported by Conte et al.10 Predictive
factors for amputation and all-cause death were evaluated.
Patients were followed up for 5 years or until December
2013 if the follow-up period was less than 5 years.
Statistical analyses. Statistical analyses were per-
formed using SPSS 21 software (IBM Corp, Armonk,
NY). Variables with a normal distribution are expressedas mean values 6 standard deviation, and asymmetrically
distributed data are given as the median and interquartile
range. Differences between the two groups were evaluated
by the Mann-Whitney test or the two-tailed paired Student
t-test for continuous variables and by c2 test for categoric
variables. Differences in event-free survival between the
two groups were examined with the Kaplan-Meier method
Table II. Independent predictors for clinical outcome after infrapopliteal bypass surgerya
Predictor
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Amputation
HD 4.92 (1.18-20.6) .029 4.36 (1.04-18.3) .045
BMI 0.86 (0.77-0.95) .0042 0.85 (0.76-0.96) .0073
CRP 1.06 (1.02-1.11) .0098 1.06 (1.02-1.11) .0095
All-cause death
HD 2.25 (1.07-4.76) .033 2.81 (1.30-6.09) .0085
Age 1.04 (1.01-1.07) .024 1.05 (1.02-1.08) .0034
CRP 1.06 (1.02-1.11) .0038 1.05 (1.01-1.10) .026
Amputation or death
HD 2.60 (1.34-5.05) .0047 2.36 (1.13-4.92) .022
BMI 0.93 (0.88-0.99) .042 0.93 (0.86-0.99) .048
CRP 1.04 (1.01-1.07) .012 1.04 (1.00-1.08) .029
BMI, Body mass index; CI, conﬁdence interval; CRP, C-reactive protein; HD, hemodialysis; HR, hazard ratio.
aVariables with P < .05 on univariate analysis were entered into a multivariate model.
Fig 2. Kaplan-Meier estimated freedom from major amputation in
hemodialysis (HD) and non-HD patients. SE, Standard error.
Fig 3. Kaplan-Meier estimated survival in hemodialysis (HD) and
non-HD patients. SE, Standard error.
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and 95% conﬁdence intervals (CIs) were calculated for each
end point by a Cox proportional hazards analysis. Variables
with P < .05 on univariate analysis were entered into a
multivariate model to determine independent predictors
for each end point. Differences were considered statistically
signiﬁcant at P < .05.
RESULTS
Ulcer/gangrene was present in 206 patients (91.2%),
and 233 limbs (98.7%) were treated using autogenous
vein grafts. Spliced vein was used in 14 HD patients
(7.6%) and in three non-HD patients (5.8%). No upper ex-
tremity veins were used because the veins must be reserved
for the arteriovenous ﬁstula in HD patients. To optimize
proximal inﬂow, additional endovascular therapy for the
femoropopliteal artery was performed in 25 HD patients
(14.1%) and 12 non-HD patients (24.5%). The proportion
of proximal inﬂow arteries and distal outﬂow arteries were
comparable between the groups. Age was younger (67 6 9vs 72 6 9 years; P ¼ .0011) and ulcer/gangrene was more
prevalent (93.8% vs 81.6%; P ¼ .0080) in HD patients than
in non-HD patients. Other clinical characteristics were
comparable (Table I).
The mortality rate during 30 days after operation was
3.4% in the HD group and 2.0% in the non-HD group
(P ¼ .62). During the follow-up period (median,
28 months), 31 HD patients (17.5%) and two non-HD pa-
tients (4.1%) needed a major amputation, 22 HD patients
(12.4%) and six non-HD patients (12.2%) underwent rein-
tervention, and 57 HD patients (32.2%) and eight non-
HD patients (16.3%) died. Kaplan-Meier analysis showed
that rate for AFS for 5 years was signiﬁcantly lower in
HD patients than in non-HD patients (43.6% vs 78.8%;
P ¼ .0033; Fig 1). On Cox multivariate analysis, HD
(adjusted HR, 2.36; 95% CI, 1.13-4.92; P ¼ .022), BMI
(adjusted HR, 0.93; 95% CI, 0.86-0.99; P ¼ .048), and
CRP (adjusted HR, 1.04; 95% CI, 1.00-1.08; P ¼ .029)
were independent predictors for the composite events
with amputation or death (Table II). Ulcer/gangrene
Fig 4. Kaplan-Meier estimated freedom from any revascularization
in hemodialysis (HD) and non-HD patients. SE, Standard error.
Table III. Independent predictors for clinical outcome










BMI 0.87 (0.27-1.56) .011 0.86 (0.76-0.97) .014
CRP 1.06 (1.01-1.13) .020 1.06 (1.01-1.11) .014
All-cause death
Age 1.05 (1.01-1.09) .0053 1.06 (1.02-1.11) .0080
CRP 1.05 (1.01-1.10) .024 1.04 (1.01-1.09) .047
Amputation or death
Age 1.03 (1.01-1.06) .015 1.02 (0.99-1.06) .059
CRP 1.04 (1.01-1.08) .033 1.03 (1.00-1.07) .037
BMI, Body mass index; CI, conﬁdence interval; CRP, C-reactive protein;
HR, hazard ratio.
JOURNAL OF VASCULAR SURGERY
Volume 61, Number 2 Kumada et al 403(HR, 2.88; 95% CI, 0.70-11.8; P ¼ .14), diabetes (HR,
1.05; 95% CI, 0.69-1.59; P ¼ .84), and additional recon-
struction for the femoropopliteal artery (HR, 1.24; 95%
CI, 0.72-5.95; P ¼ .44) were not identiﬁed as signiﬁcant
predictors. Similarly, the 5-year freedom from amputation
was signiﬁcantly lower in HD patients than in non-HD
patients (72.4% vs 92.5%; P ¼ .015), and the survival
rate was 56.9% and 83.2% (P ¼ .029), respectively (Figs
2 and 3). HD patients also had an independent risk for
major amputation (adjusted HR, 4.36; 95% CI, 1.04-
18.3; P ¼ .045) and for death (adjusted HR, 2.81; 95%
CI, 1.30-6.09; P ¼ .0085; Table II). However, freedom
from reintervention was comparable between the HD
and non-HD groups (84.3% vs 86.8%; P ¼ .89; Fig 4).
In HD patients, BMI (adjusted HR, 0.86; 95% CI,
0.76-0.96 per 1-kg/m2 increase; P ¼ .014) and serum
CRP (adjusted HR, 1.06; 95% CI, 1.01-1.11; P ¼ .014)
were identiﬁed as independent predictors for major ampu-
tation. Elevated CRP levels were also associated with
death (adjusted HR, 1.04; 95% CI, 1.01-1.09; P ¼
.047; Table III). In contrast, neither BMI (HR, 0.89;
95% CI, 0.57-1.32; P ¼ .52) nor CRP (HR, 1.02; 95%
CI, 0.77-1.34; P ¼ .89) was recognized as a predictor
for amputation in non-HD patients, and elevated CRP
also was not associated with death (HR, 1.02; 95% CI,
0.98-1.06; P ¼ .31).
DISCUSSION
Numerous studies have revealed that renal insufﬁciency
is consistently associated with poor outcome after lower ex-
tremity revascularization, regardless of surgical or percuta-
neous procedure.1-3,7-9 The risk of amputation or death
after bypass surgery gradually increases according to the
progression of stage of chronic kidney disease (CKD);
especially, ESRD requiring HD has been the highest risk
factor of poor AFS among signiﬁcant predictors such as tis-
sue loss, advanced age, anemia, or history of coronary ar-
tery disease.1,2
HD patients have thus been considered a challenged pop-
ulation with poor prognosis after bypass surgery.3 In this re-
gard, similar results were also obtained in the present study,
with a four-times higher risk of amputation and three-times
higher risk of death after infrapopliteal bypass surgery in
HD patients compared with non-HD patients. However,
the 5-year survival rate in the study was 57%, which might
be very similar to the 59% survival in average Japanese HD pa-
tients reported by the Japanese Society of Dialysis Therapy.11
The 5-year freedom from amputation of 72% in the
present study might also be superior to that of 50% in
CKD stage 5 patients with peripheral artery disease,
including CLI, in the United States.2 Thus, these out-
comes seemed fully acceptable even though HD patients
in Japan are reported to have better survival than those in
the United States and Europe.12,13 In addition, the risk
of subclinical atherosclerosis is lower in the Japanese
population.14
Interestingly, the present study identiﬁed preoperative
low BMI and elevated CRP levels as the predictors ofamputation or death, or both, in HD patients but not in
non-HD patients, although both values were comparable
between the two groups. Currently, protein-energy
wasting (PEW), deﬁned as the state of decreased body
stores of protein and energy fuels, has been reported to
be common and strongly associated with cardiovascular
risk in CKD patients.15 PEW was also considered to be
due to the inﬂammatory process rather than to poor nutri-
tional intake, and CKD-speciﬁc comorbidity, which used to
be called malnutrition, inﬂammation, and atherosclerosis
syndrome.16 Thus, the declined BMI, as an established
marker of PEW and elevated CRP, could consistently pre-
dict poor survival in this population.17,18
We also have reported that elevated CRP levels were
associated with a high restenosis rate and death after coro-
nary drug-eluting stenting or with a high amputation rate
and death after endovascular therapy in chronic HD pa-
tients.19,20 By the way, serum creatinine or urea nitrogen
levels were comparable among quartiles according to
JOURNAL OF VASCULAR SURGERY
404 Kumada et al February 2015CRP levels in our previous study.18 Thus, the elevated CRP
levels do not seems to reﬂect kidney dysfunction but rather
the state of chronic inﬂammation.
In this regard, preoperative comorbid conditions, such
as the PEW state or chronic inﬂammation, should be more
carefully observed in this population than in the general
population. However, the reintervention rate was compara-
ble between the two groups despite the poorer limb salvage
rate or mortality in HD group compared with non-HD
group. This discrepancy has been frequently observed in
previous studies.2,3,20 Owens et al2 clariﬁed a strong rela-
tionship of CKD category with amputation or death, or
both, but not with graft patency after lower extremity
bypass surgery. Lantis et al21 also reported that amputa-
tion, despite a patent graft, was needed in 10% to 15% of
ESRD patients with CLI and that this reﬂected their
poor substrate for wound healing and sepsis control after
infrainguinal bypass surgery. These results might be also
potentially explained due to the presence of PEW or
chronic inﬂammation in CKD patients.
Thee present study has several limitations. First, the
number of non-HD patients enrolled as the control group
seemed too small compared with that of the HD patients
because our institutes are core hospitals associated with
many HD clinics. Second, all enrolled subjects were Japa-
nese, who have lower atherosclerotic burden or mortality
rate than patients in Europe or the United States, as
mentioned.12-14 Third, the study did not evaluate the sta-
tus of precise medication use at baseline or during the
follow-up period, although pharmacologic intervention
may greatly affect the clinical outcome.
CONCLUSIONS
The clinical outcome after infrapopliteal bypass surgery
was obviously poorer in HD patients with CLI compared
with non-HD patients, but seemed to be acceptable. Spe-
ciﬁc comorbidities, such as the PEW state or chronic
inﬂammation, were associated with the poor outcome in
this population.
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